As of December 31, 2022, the Company had total cash and cash equivalents of approximately $29.7 million, compared to approximately $39.4 million as of September 30, 2022. Included in total cash and cash equivalents was approximately $17.0 million and $23.5 million of restricted cash as of December 31, 2022 and September 30, 2022, respectively. Subsequent to year-end December 2022, the Company amended its convertible note and repaid approximately $16.8 million that was previously classified as restricted cash. In March 2023, the Company raised $5 million in gross proceeds through a registered direct offering. The Company anticipates that its cash runway is sufficient to fund operations into the third quarter of 2023.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NMTR:
- 9 Meters Biopharma cut to Hold at Truist on cash overhang, lack of catalysts
- 9 Meters Biopharma downgraded to Hold from Buy at Truist
- 9 Meters Biopharma price target lowered to $1.70 from $2.70 at Citi
- 9 Meters Biopharma announces $5M registered direct offering priced at $1.60
- 9 Meters Biopharma confirms it doesn’t hold deposits, securities at SVB